Detailed Information on Publication Record
2021
On Predicting Recurrence in Early Stage Non-small Cell Lung Cancer
MOHAMED, Sameh K., Brian WALSH, Mohan TIMILSINA, Maria TORRENTE, Fabio FRANCO et. al.Basic information
Original name
On Predicting Recurrence in Early Stage Non-small Cell Lung Cancer
Authors
MOHAMED, Sameh K., Brian WALSH, Mohan TIMILSINA, Maria TORRENTE, Fabio FRANCO, Mariano PROVENCIO, Adrianna JANIK, Luca COSTABELLO, Pasquale MINERVINI, Pontus STENETORP and Vít NOVÁČEK (203 Czech Republic, guarantor, belonging to the institution)
Edition
San Diego, Proceedings of AMIA 2021 Annual Symposium, p. 853-862, 10 pp. 2021
Publisher
AMIA
Other information
Language
English
Type of outcome
Stať ve sborníku
Field of Study
10201 Computer sciences, information science, bioinformatics
Country of publisher
United States of America
Confidentiality degree
není předmětem státního či obchodního tajemství
Publication form
electronic version available online
RIV identification code
RIV/00216224:14330/21:00125683
Organization unit
Faculty of Informatics
ISSN
Keywords in English
machine learning; lung cancer; relapse prediction
Tags
International impact, Reviewed
Změněno: 2/1/2023 10:10, doc. Mgr. Bc. Vít Nováček, PhD
Abstract
V originále
Early detection and mitigation of disease recurrence in non-small cell lung cancer (NSCLC) patients is a nontrivial problem that is typically addressed either by rather generic follow-up screening guidelines, self-reporting, simple nomograms, or by models that predict relapse risk in individual patients using statistical analysis of retrospective data. We posit that machine learning models trained on patient data can provide an alternative approach that allows for more efficient development of many complementary models at once, superior accuracy, less dependency on the data collection protocols and increased support for explainability of the predictions. In this preliminary study, we describe an experimental suite of various machine learning models applied on a patient cohort of 2442 early stage NSCLC patients. We discuss the promising results achieved, as well as the lessons we learned while developing this baseline for further, more advanced studies in this area.